Performance Parameters of the Conventional Serological Markers for Autoimmune Hepatitis

Overview

Journal Dig Dis Sci

Specialty Gastroenterology

Date 2010 Dec 4

PMID 21127976

Citations 31

Authors

Albert J Czaja

Affiliations

Soon will be listed here.

Abstract

Background: Autoimmune hepatitis is defined by a conventional battery of autoantibodies that may also be present in other liver diseases.

Aims: To define the performance parameters of the conventional autoantibodies for autoimmune hepatitis, determine the diagnostic implications of simultaneous autoantibody production, and assess the performances of serological assays based on indirect immunofluorescence and enzyme immunoassay.

Methods: In this study, 265 adults satisfying codified criteria for autoimmune hepatitis and 342 adults who satisfied conventional diagnostic criteria for another chronic liver disease were each assessed for the conventional autoantibodies.

Results: Antinuclear antibodies, smooth muscle antibodies, and antibodies to liver kidney type 1 had sensitivities of only 32, 16, and 1%, respectively, for the diagnosis of autoimmune hepatitis, and their diagnostic accuracy ranged from 56 to 61%. The combination of antinuclear antibodies and smooth muscle antibodies at presentation had superior sensitivity (43%), specificity (99%), positive (97%) and negative (69%) predictabilities, and diagnostic accuracy (74%) than each marker alone. The occurrence of multiple autoantibodies was lower in other chronic liver diseases than in autoimmune hepatitis (8% versus 51%, p < 0.000001). The enzyme immunoassay for antinuclear antibodies had an accuracy that was not discriminative for autoimmune hepatitis (p = 0.06).

Conclusions: Isolated autoantibodies have a low diagnostic accuracy for autoimmune hepatitis. Concurrent antinuclear antibodies and smooth muscle antibodies have superior performance parameters. The enzyme immunoassay for antinuclear antibodies performs less well than the assay based on indirect immunofluorescence.

Citing Articles

Immune-mediated liver injury from checkpoint inhibitors: mechanisms, clinical characteristics and management.

Triantafyllou E, Gudd C, Possamai L Nat Rev Gastroenterol Hepatol. 2024; 22(2):112-126.

PMID: 39663461 DOI: 10.1038/s41575-024-01019-7.

Autoimmune Hepatitis: A Diagnostic and Therapeutic Overview.

Mercado L, Gil-Lopez F, Chirila R, Harnois D Diagnostics (Basel). 2024; 14(4).

PMID: 38396421 PMC: 10887775. DOI: 10.3390/diagnostics14040382.

Autoimmune hepatitis: Brighton Collaboration case definition and guidelines for data collection, analysis, and presentation of immunisation safety data.

Kochhar S, Assis D, Mack C, Izurieta H, Muratori L, Munoz A Vaccine. 2024; 42(7):1812-1825.

PMID: 38368225 PMC: 11648169. DOI: 10.1016/j.vaccine.2024.01.021.

Autoimmune liver disease and multiple sclerosis: state of the art and future perspectives.

Villani R, Serviddio G, Avolio C, Cassano T, DAmico E Clin Exp Med. 2023; 23(7):3321-3338.

PMID: 37421590 PMC: 10618321. DOI: 10.1007/s10238-023-01128-8.

Post-COVID-19 polyautoimmunity - Fact or coincidence: A case report.

Shorbagi A, Obaideen A, Jundi M Front Med (Lausanne). 2023; 10:1013125.

PMID: 37007767 PMC: 10060632. DOI: 10.3389/fmed.2023.1013125.

References

Czaja A, CARPENTER H, Santrach P, Moore S . Immunologic features and HLA associations in chronic viral hepatitis. Gastroenterology. 1995; 108(1):157-64. DOI: 10.1016/0016-5085(95)90020-9. View

Czaja A . Autoantibodies as prognostic markers in autoimmune liver disease. Dig Dis Sci. 2010; 55(8):2144-61. DOI: 10.1007/s10620-010-1268-4. View

Nezu S, Tanaka A, Yasui H, Imamura M, Nakajima H, Ishida H . Presence of antimitochondrial autoantibodies in patients with autoimmune hepatitis. J Gastroenterol Hepatol. 2006; 21(9):1448-54. DOI: 10.1111/j.1440-1746.2006.04434.x. View

Czaja A, Norman G . Autoantibodies in the diagnosis and management of liver disease. J Clin Gastroenterol. 2003; 37(4):315-29. DOI: 10.1097/00004836-200310000-00011. View

Czaja A, Santrach P, Moore S . Shared genetic risk factors in autoimmune liver disease. Dig Dis Sci. 2001; 46(1):140-7. DOI: 10.1023/a:1005670111068. View

Czaja A . The role of autoantibodies as diagnostic markers of autoimmune hepatitis. Expert Rev Clin Immunol. 2010; 2(1):33-48. DOI: 10.1586/1744666X.2.1.33. View

Bernstein R, Neuberger J, Bunn C, Callender M, Hughes G, Williams R . Diversity of autoantibodies in primary biliary cirrhosis and chronic active hepatitis. Clin Exp Immunol. 1984; 55(3):553-60. PMC: 1535919. View

Czaja A, Freese D . Diagnosis and treatment of autoimmune hepatitis. Hepatology. 2002; 36(2):479-97. DOI: 10.1053/jhep.2002.34944. View

Lindor K, Gershwin M, Poupon R, Kaplan M, Bergasa N, Heathcote E . Primary biliary cirrhosis. Hepatology. 2009; 50(1):291-308. DOI: 10.1002/hep.22906. View

10.

Miyakawa H, Kikuchi K, Kawaguchi N, Yajima R, Ito Y, Maekubo H . High sensitivity of a novel ELISA for anti-M2 in primary biliary cirrhosis. J Gastroenterol. 2001; 36(1):33-8. DOI: 10.1007/s005350170151. View

11.

Chapman R, Fevery J, Kalloo A, Nagorney D, Boberg K, Shneider B . Diagnosis and management of primary sclerosing cholangitis. Hepatology. 2010; 51(2):660-78. DOI: 10.1002/hep.23294. View

12.

Lok A, McMahon B . Chronic hepatitis B: update 2009. Hepatology. 2009; 50(3):661-2. DOI: 10.1002/hep.23190. View

13.

Leung P, Rossaro L, Davis P, Park O, Tanaka A, Kikuchi K . Antimitochondrial antibodies in acute liver failure: implications for primary biliary cirrhosis. Hepatology. 2007; 46(5):1436-42. PMC: 3731127. DOI: 10.1002/hep.21828. View

14.

HOMBERG J, Abuaf N, Bernard O, Islam S, Alvarez F, Khalil S . Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of "autoimmune" hepatitis. Hepatology. 1987; 7(6):1333-9. DOI: 10.1002/hep.1840070626. View

15.

Mishima S, Omagari K, Ohba K, Kadokawa Y, Masuda J, Mishima R . Clinical implications of antimitochondrial antibodies in type 1 autoimmune hepatitis: a longitudinal study. Hepatogastroenterology. 2008; 55(81):221-7. View

16.

Loria P, Lonardo A, Leonardi F, Fontana C, Carulli L, Verrone A . Non-organ-specific autoantibodies in nonalcoholic fatty liver disease: prevalence and correlates. Dig Dis Sci. 2004; 48(11):2173-81. DOI: 10.1023/b:ddas.0000004522.36120.08. View

17.

Czaja A, Donaldson P . Gender effects and synergisms with histocompatibility leukocyte antigens in type 1 autoimmune hepatitis. Am J Gastroenterol. 2002; 97(8):2051-7. DOI: 10.1111/j.1572-0241.2002.05921.x. View

18.

Vergani D, Alvarez F, Bianchi F, Cancado E, Mackay I, Manns M . Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. J Hepatol. 2004; 41(4):677-83. DOI: 10.1016/j.jhep.2004.08.002. View

19.

Homburger H, Cahen Y, Griffiths J, Jacob G . Detection of antinuclear antibodies: comparative evaluation of enzyme immunoassay and indirect immunofluorescence methods. Arch Pathol Lab Med. 1998; 122(11):993-9. View

20.

Czaja A . Clinical features, differential diagnosis and treatment of autoimmune hepatitis in the elderly. Drugs Aging. 2008; 25(3):219-39. DOI: 10.2165/00002512-200825030-00005. View